Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
F. Hoffmann-La Roche AG, commonly known as Roche, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Basel, Switzerland (CH). Founded in 1896, Roche has established itself as a pioneer in innovative healthcare solutions, focusing on pharmaceuticals and diagnostics. The company operates extensively across Europe, North America, and Asia, delivering cutting-edge treatments in oncology, immunology, and infectious diseases.
Roche is renowned for its unique combination of pharmaceuticals and diagnostic tools, enabling personalised medicine that enhances patient outcomes. With a strong market position, Roche consistently ranks among the top global pharmaceutical companies, recognised for its commitment to research and development. Notable achievements include significant advancements in cancer therapies and a robust pipeline of biologic drugs, solidifying its reputation as a leader in the healthcare sector.
+16 vs industry average
F. Hoffmann-La Roche AG’s score of 58 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
F. Hoffmann-La Roche AG, a Swiss pharmaceutical preparation manufacturer, reported total emissions of approximately 8.32 billion kg CO2e in 2021. This total includes Scope 1 emissions of about 254.06 million kg CO2e, Scope 2 emissions of approximately 168.74 million kg CO2e, and Scope 3 emissions of around 7.89 billion kg CO2e. Key contributors to Scope 3 emissions were purchased goods and services (approximately 6.79 billion kg CO2e), capital goods (around 589.32 million kg CO2e), and upstream transportation and distribution (approximately 228.27 million kg CO2e).
The company is committed to achieving net-zero emissions across its entire value chain by 2045, starting from 2023. While F. Hoffmann-La Roche AG reports its own performance data, its SBTi and CDP initiatives are cascaded from its parent company, Roche Holding AG.
2045
90% reduction in Scope 2
F. Hoffmann-La Roche Ltd commits to reduce absolute scope 2 GHG emissions 90% by 2045 from a 2022 base year.
2045
90% reduction in scope 3 total
F. Hoffmann-La Roche Ltd also commits to reduce absolute scope 3 GHG emissions 90% within the same timeframe.
2045
90% reduction in Scope 1
F. Hoffmann-La Roche Ltd commits to reduce absolute scope 1 GHG emissions 90% by 2045 from a 2022 base year.
See all 7 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about F. Hoffmann-La Roche AG’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more